Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Why G3139 works poorly in cancer trials but might work well against HIV

George E. Parris*

9601 Warfield Road, Gaithersburg, MD 20882, USA

Received 25 December 2006; accepted 7 January 2007

Summary  The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2. To date, its effectiveness in cancer clinical trials has been minimal. Some suggestions are provided for that disappointment and recent citations are provided that support the idea that G3139 may be effective at clearing viral infections, specifically HIV. At the time G3139 was conceived as an anti-cancer drug candidate, it was viewed optimistically because Bcl-2 was widely believed to be the most important protein blocking p53-dependent apoptosis caused by internal stress. Since that time, we have learnt that Bcl-2 is not the only protein that inhibits apoptosis and that p53 itself is frequently malfunctioning in tumors. Thus, the anti-cancer utility of suppressing Bcl-2 in cancer cells is limited. Moreover, Bcl-2 has a role in halting the cell cycle (though p27), which may slow down tumor growth; and Bcl-2 even has pro-apoptotic roles in the execution of apoptosis initiated by external death signals (via Fas/CD95 and caspase 3). Overall, in the clinical setting, G3139 usually has statistically significant but medically unimportant benefit. These results have greatly diminished the enthusiasm for the drug especially when the side effects are considered. Specifically, the unmethylated CpG ODN (and/or the phosphorothioate group) activates the immune system, but this potentially important anti-cancer effect is lost when the immune cells undergo premature apoptosis apparently because their Bcl-2 levels have been lowered by the antisense effect of G3139. While this effect on immune cells is usually undesirable, it is exactly what would be useful for activating immune cells, initiating provirus transcription in retrovirus-infected cells, and facilitating selective apoptosis of these infected cells. In general, G3139 might have benefit in clearing chronic infections by intracellular parasites including viruses (HIV, SIV, HTLV, HBV, coronavirus, etc.). Indeed, G3139 has been shown to cause apoptosis in EBV-infected cells leading to clearance of the virus.

© 2007 Elsevier Ltd. All rights reserved.

The antisense drug G3139 (oblimersen sodium, Genta, Inc.) is a phosphorothioate oligodeoxynucleotide (ODN) containing unmethylated CpG units, which is targeted to suppress Bcl-2 [1–4]. It was expected that reduction of Bcl-2 levels would facilitate apoptosis in drug-resistant cancer cells [1,2].

Over the last several years [3,4], G3139 has been evaluated in several phase III cancer clinical trials and (unfortunately) it only slightly improves the performance of classical chemotherapeutic agents. I hypothesize that this disappointment is in part due to the fact that most cancer clones have lost p53 activity [5]. Internal stresses of various sorts (metabolic, physical, genotoxic) are communicated to p53 via independent signaling pathways.
and p53 integrates them into a single level of cellular stress that activates p21 to slow down the cell cycle [6]. If delaying the cell cycle does not allow the cellular stress to be mitigated (e.g., by DNA repair; restoration of pH, Eh or nutrient levels; metabolism or excretion of toxins), then activated p53 reaches a level that summons pro-apoptotic proteins (e.g., Bax and Bak), which initiate apoptosis [7]. Bcl-2 fine-tunes the threshold of stress at which apoptosis occurs by blocking the action of the pro-apoptotic proteins (Fig. 1).

This p53-dependent pathway is apparently absent in the majority of cancer clones as shown by the utility of p53 gene therapy (e.g., with Ad5CMV-p53, Advexin(R), Introgen Therapeutics, Inc.) [8]. Thus, suppression of Bcl-2 in combination with classical chemotherapy, which induces internal stress (e.g., genotoxicity), cannot have much positive effect on apoptosis of abnormal cells [4]. On the other hand, it would appear that a combination of drugs that: (i) restores p53 activity, (ii) suppresses Bcl-2, (iii) induces internal stress in cancer cells, and (iv) suppresses cell fusion [9] would be an attractive candidate for clinical trials.

Another possible reason that G3139 has been of little benefit in cancer clinical trials has to do with the fact that Bcl-2 works to suspend the cell cycle via p27 [10–12]. In some cancers, this may be the only inhibition remaining to block an uncontrolled cell cycle. Obviously, in this case, suppressing Bcl-2 would be undesirable unless it led immediately to apoptosis.

Finally, G3139 has another important feature. Namely, it is an unmethylated CpG compound that has been extensively tested in clinical trials. Unmethylated CpG compounds are known to stimulate immune response by activating leucocytes [13]. This would appear to have desirable anti-cancer effects and may, indeed, account for some of the G3139 benefit in pre-clinical studies, but as shown in Fig. 1, Bcl-2 actually plays an important role in inducing apoptosis triggered by external death signals. Specifically, binding of Fas (CD95) on the cell surface (by FasL, TNF, etc.) activates caspase-3, which cleaves Bcl-2 into pro-apoptotic Bax-like fragments [14]. Ironically, G3139 suppresses Bcl-2 such that the benefit of the enhanced immune response (external stress) against tumors appears to be largely lost.

---

**Figure 1** Summary of major pathways leading to apoptosis following damage to DNA that can lead to mutations.
Indeed, this effect of G3139 appears to lead to significant adverse toxicity in cancer trials. G3139 has been shown to suppress Bcl-2 in T-cells, B-cells and monocytes [3]. The combination of activation of immune cells and blocking their Bcl-2 expression leads to substantial apoptosis and neutropenia and thrombocytopenia [4]. It seems clear that G3139 is having an effect in the cells that become infected with HIV [15,16]. It is probably undesirable to treat individuals who have very low levels of T-cells with G3139. If, however, T-cell levels have been stabilized with HAART [17], then G3139 may well activate transcription of the latent HIV provirus inducing internal stress in the infected T-cells that is not present in the uninfected (bystander) T-cells. Bcl-2 over-expression is essential for the survival of HIV-infected cells that are actively transcribing the provirus [18,19]. Hence, without the benefit of elevated Bcl-2, these activated, HIV-infected T-cells should preferentially undergo apoptosis. At the same time, lowering the Bcl-2 levels in bystander T-cells makes them less susceptible to external death signals. Thus, suppression of Bcl-2 should concurrently protect uninfected cells from the ravages of HIV-infected T-cells.

This hypothesis was originally published in 2004 [20,21] and to my knowledge, no one with means to test it has given it serious consideration. The results of G3139 clinical trials have greatly reduced the enthusiasm for G3139 as an anti-cancer drug. But, the report [22] that G3139 has successfully eliminated EBV+ nasopharyngeal carcinoma xenografts in SCID mice suggests that the drug does eliminate the barriers to viral (internal) stress induced apoptosis. If it turns out that HIV suppresses cellular p53 [23,24] as well as causing over-expression of cellular Bcl-2, then steps to restore p53 function might be necessary.

References

[1] Raynaud FI, Orr RM, Godard PM, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to Bcl-2 after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997;281:420–7.
[2] Bettaieb A, Dubrez-Daloz L, Launay S, et al. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. Curr Med Chem Anticancer Agents 2003;3:307–18.
[3] van de Donk NW, de Weerdt O, Veth G, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia. 2004;18:1078–84.
[4] Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738–45.
[5] Lim YP, Lim TT, Chan YL. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 2006 (September) [Epub ahead of print].
[6] Barboza JA, Liu G, Ju Z, El-Naggar AK. Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006 (December) [Epub ahead of print].
[7] White E. Mechanisms of apoptosis regulation by viral oncoproteins in infection and tumorigenesis. Cell Death Diff 2006;13:1371–7.
[8] Gabrilovich DI. INGN 201 (Advexin): adeno/valir p53 gene therapy for cancer. Expert Opin Biol Ther 2006;6:823–32.
[9] Parris GE. The cell clone ecology hypothesis and the cell fusion model of cancer progression and metastasis: history and experimental support. Med Hypotheses 2006;66:76–83.
[10] Crescenzi E, Palumbo G, Brady HJ. Bcl-2 activates a programme of premature senescence in human carcinoma cells. Biochem J 2003;375:263–74.
[11] Cheng N, Janumyan YM, Didion L, Van Hofwegen C, Yang E, Knudson CM. Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene. 2004;23:3770–80.
[12] Li WQ, Jiang Q, Aleeem E, Kaldis P, Khaled AR, Durum SK. IL-7 promotes T cell proliferation through destabilization of p27Kip1. J Exp Med 2006;203:573–82.
[13] Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 2002;20:709–60.
[14] Del Bello B, Valentini MA, Zunino F, Comporti M, Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene. 2001;20:4591–5.
[15] Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337–40.
[16] Rossi G, Gorla R, Stellini R, et al. Prevelence, clinical, and laboratory features of thrombocytopenia among HIV-infected individuals. Aids Res Hum Retroviruses 1990;6:261–9.
[17] Siliciano R. HARRT for life. Hopkins HIV Rev 1999;11:2.
[18] Babhoui B, Landay A, Al-Harthi L. Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood. 2004;103:4581–7.
[19] Arnoult D, Petit F, Lecler B, et al. Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Diff 2003;10:1240–52.
[20] Parris GE. Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. Med Hypotheses 2004;62:354–7.
[21] Parris GE. AIDS: caused by development of resistance to drugs in a non-target intracellular parasite. Med Hypotheses 2007;68:151–7.
[22] Lacy J, Loomis R, Grill S, Srimatkandada P, Carbone R, Cheng YC. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 2006;119:309–16.
cellular Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol 2006 (November) [Epub ahead of print].

[24] Pauls E, Senserrich J, Clotet B, Este JA. Inhibition of HIV-1 replication by RNA interference of p53 expression. J Leukoc Biol 2006;80:659–67.